Improved Revenues Required Before Idorsia Ltd (VTX:IDIA) Stock's 71% Jump Looks Justified
Dec 19
Have your own idea? Try our Stock Screener
Swiss (SMI) Biotech Industry Analysis
UpdatedFeb 06, 2025
DataAggregated Company Financials
Companies6
- 7D2.3%
- 3M-9.1%
- 1Y99.0%
- YTD3.8%
Over the last 7 days, the Biotech industry has dropped 2.7%, driven by Molecular Partners declining 3.3%. On the other hand Santhera Pharmaceuticals Holding is actually up 11%. In the past year, the industry has gained 91%. Earnings are forecast to grow by 8.7% annually.
Industry Valuation and Performance
Has the Swiss Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 06 Feb 2025 | CHF 1.7b | CHF 330.3m | -CHF 75,131,868.00 | 3.4x | -22.9x | 5.2x |
| Sat, 04 Jan 2025 | CHF 1.7b | CHF 330.3m | -CHF 75,131,868.00 | 2.8x | -22.8x | 5.2x |
| Mon, 02 Dec 2024 | CHF 1.7b | CHF 330.9m | -CHF 87,805,465.00 | 1.6x | -19.4x | 5.1x |
| Wed, 30 Oct 2024 | CHF 1.9b | CHF 333.1m | -CHF 82,023,629.00 | 1.8x | -23.1x | 5.7x |
| Fri, 27 Sep 2024 | CHF 1.5b | CHF 333.6m | -CHF 81,088,264.00 | 1.7x | -19.1x | 4.6x |
| Sun, 25 Aug 2024 | CHF 1.4b | CHF 319.7m | -CHF 142,008,264.00 | 1.9x | -10x | 4.4x |
| Tue, 23 Jul 2024 | CHF 746.2m | CHF 151.7m | -CHF 146,197,264.00 | 1.6x | -5.1x | 4.9x |
| Thu, 20 Jun 2024 | CHF 800.2m | CHF 151.7m | -CHF 146,197,264.00 | 1.6x | -5.5x | 5.3x |
| Sat, 18 May 2024 | CHF 538.2m | CHF 170.7m | -CHF 134,962,764.00 | 1x | -4x | 3.2x |
| Mon, 15 Apr 2024 | CHF 451.9m | CHF 67.6m | -CHF 173,099,120.58 | 0.1x | -2.6x | 6.7x |
| Wed, 13 Mar 2024 | CHF 355.5m | CHF 55.5m | -CHF 173,258,224.22 | 0.3x | -2.1x | 6.4x |
| Fri, 09 Feb 2024 | CHF 365.6m | CHF 55.4m | -CHF 173,287,535.62 | 1x | -2.1x | 6.6x |
| Sun, 07 Jan 2024 | CHF 324.0m | CHF 317.4m | -CHF 176,097,332.00 | 0.5x | -1.8x | 1x |
| Tue, 05 Dec 2023 | CHF 340.1m | CHF 317.8m | -CHF 208,920,007.00 | n/a | -1.6x | 1.1x |
| Thu, 02 Nov 2023 | CHF 253.7m | CHF 318.6m | -CHF 211,518,481.00 | n/a | -1.2x | 0.8x |
| Sat, 30 Sep 2023 | CHF 262.4m | CHF 318.8m | -CHF 219,583,688.00 | n/a | -1.2x | 0.8x |
| Mon, 28 Aug 2023 | CHF 302.2m | CHF 318.7m | -CHF 188,690,006.00 | n/a | -1.6x | 0.9x |
| Wed, 26 Jul 2023 | CHF 349.3m | CHF 322.2m | -CHF 179,787,126.00 | n/a | -1.9x | 1.1x |
| Fri, 23 Jun 2023 | CHF 303.9m | CHF 331.2m | -CHF 180,833,676.00 | n/a | -1.7x | 0.9x |
| Sun, 21 May 2023 | CHF 351.7m | CHF 331.2m | -CHF 183,199,380.00 | n/a | -1.9x | 1.1x |
| Tue, 18 Apr 2023 | CHF 425.1m | CHF 481.3m | CHF 8.2m | 1.5x | 51.9x | 0.9x |
| Thu, 16 Mar 2023 | CHF 422.9m | CHF 494.3m | CHF 15.0m | 1.5x | 28.2x | 0.9x |
| Sat, 11 Feb 2023 | CHF 483.0m | CHF 493.4m | CHF 14.5m | 1.7x | 33.3x | 1x |
| Mon, 09 Jan 2023 | CHF 503.1m | CHF 493.4m | CHF 14.5m | 1.6x | 34.7x | 1x |
| Wed, 07 Dec 2022 | CHF 513.1m | CHF 493.4m | CHF 14.5m | 1.8x | 35.4x | 1x |
| Fri, 04 Nov 2022 | CHF 508.5m | CHF 509.5m | CHF 14.9m | 1.8x | 34.2x | 1x |
| Sun, 02 Oct 2022 | CHF 521.6m | CHF 505.3m | CHF 15.9m | 2x | 32.8x | 1x |
| Tue, 30 Aug 2022 | CHF 519.6m | CHF 497.9m | CHF 36.7m | 1.7x | 14.1x | 1x |
| Thu, 28 Jul 2022 | CHF 518.1m | CHF 487.8m | CHF 42.2m | 1.8x | 12.3x | 1.1x |
| Sat, 25 Jun 2022 | CHF 540.7m | CHF 454.1m | CHF 80.7m | 2.1x | 6.7x | 1.2x |
| Mon, 23 May 2022 | CHF 719.6m | CHF 471.4m | CHF 25.1m | 2.1x | 28.6x | 1.5x |
| Wed, 20 Apr 2022 | CHF 1.1b | CHF 293.2m | -CHF 142,349,433.00 | 1.5x | -7.4x | 3.6x |
| Fri, 18 Mar 2022 | CHF 1.2b | CHF 284.2m | -CHF 137,157,645.00 | 2x | -8.9x | 4.3x |
| Sun, 13 Feb 2022 | CHF 1.4b | CHF 282.9m | -CHF 138,870,474.00 | 1.8x | -10x | 4.9x |
Price to Earnings Ratio
-10x
Current Industry PE
- Investors are optimistic on the Swiss Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 2.7x is lower than the industry's current PS ratio of 5.3x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Revenues for these companies have grown 5.3% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Trends
Which industries have driven the changes within the Swiss Healthcare industry?
| CH Market | 0.13% | |
| Healthcare | 3.60% | |
| Biotech | 2.30% | |
| Biotech | 2.30% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| BSLN Basilea Pharmaceutica | CHF 40.70 | 1.1% +CHF 5.5m | 26.2% | PS3.3x | |
| SANN Santhera Pharmaceuticals Holding | CHF 16.72 | 2.0% +CHF 5.4m | 79.2% | PE3.4x | |
| SPEX Spexis | CHF 0.031 | 210.0% +CHF 1.4m | -87.6% | PS3.5x |
